Consensus recommendations for the treatment of migraine prevention
Miguel Ángel Calleja-Hernández 1 , Ángel Luis Guerrero-Peral 2 , Pablo Irimia-Sieira 3 , Icíar Martínez-López 4 , Sonia Santos-Lasaosa 5 , Maite Sarobe-Carricas 6 , José María Serra López-Matencio 7 , José Miguel Láinez-Andrés 8
Objective: The objectives are to know the opinion of neurologists and hospital pharmacists on those aspects still under debate regarding the role of anti-CGRP monoclonal antibodies in the preventive treatment of migraine. To identify those controversies that still exist. To propose agreed recommendations for improvement of care. And to promote access of clinicians and patients to these new treatments in the prevention of migraine with biological drugs, in order to improve patient care and follow-up.
Methodology: Recommendations for the use of biological drugs in the prevention of migraine were identified and evaluated through the Delphi consensus methodology, proposing 88 statements grouped into three themes: a clinical module that deals with the management of biological treatments in migraine; a patient module that discusses patient education and adherence improvement strategies; and a coordination module that includes statements related to strategies to improve joint work between the two groups. The 9-point Likert ordinal scale was used to score these recommendations and, subsequently, the data was statistically analyzed through different metrics.
Results: After both rounds of voting, consensus was reached in agreement on 71 of the 88 statements (80.7%), leaving one statement (1.1%) with consensus in disagreement and 16 remaining as indeterminate (18.2%).
Conclusions: The high degree of consensus indicates that the opinion of neurologists and hospital pharmacists on the role of anti-CGRP monoclonal antibodies in the treatment of migraine is very similar and allows identifying those controversies that still exist, to improve the care and follow-up of patients with migraine.
CITATION Farm Hosp. 2023 Jun 13;S1130-6343(23)00035-1. doi: 10.1016/j.farma.2023.03.011